Assmann, Jorn L. J. C. http://orcid.org/0000-0002-6947-8905
Leon, Leticia G. http://orcid.org/0000-0001-8781-7424
Stavast, Christiaan J. http://orcid.org/0000-0003-1460-3112
van den Bogaerdt, Sanne E.
Schilperoord-Vermeulen, Joyce
Sandberg, Yorick
Bellido, Mar http://orcid.org/0000-0001-9864-5816
Erkeland, Stefan J. http://orcid.org/0000-0002-1019-7957
Feith, David J. http://orcid.org/0000-0003-4981-1691
Loughran Jr, Thomas P.
Langerak, Anton W. http://orcid.org/0000-0002-2078-3220
Article History
Received: 5 May 2021
Revised: 8 November 2021
Accepted: 15 November 2021
First Online: 6 December 2021
Competing interests
: TPL is on the Scientific Advisory Board and has stock options for Keystone Nano, Bioniz Therapeutics and Dren Bio. TPL and DJF have received honoraria from Kymera Therapeutics. There are no conflicts of interest with the work presented in this manuscript. All other authors declare no conflicts of interest with the work presented in this study.